Want to see JP:4598 full AI Analyst Report?
Delta-Fly Pharma, Inc. (4598) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Dfp-10917 | Leukemia, Myeloid, Acute | phase1AndPhase2 | Recruiting | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Apr 19, 2024 | ― |
| Dfp-14927 | Cancer, Solid Tumor | Phase I | Recruiting | Trial of DFP-14927 in Advanced Solid Tumors | Apr 25, 2019 | ― |
| Fludarabine, Azacitidine, Cytarabine, Decitabine, Venetoclax, Etoposide, Idarubicin, Mitoxantrone, Dfp-10917, Cladribine | Leukemia, Myeloid, Acute | Phase III | Recruiting | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Apr 11, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Venetoclax, Dfp-10917 | phase1AndPhase2 | Leukemia, Myeloid, Acute | Recruiting | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Apr 19, 2024 | ― |
| Dfp-14927 | Phase I | Cancer, Solid Tumor | Recruiting | Trial of DFP-14927 in Advanced Solid Tumors | Apr 25, 2019 | ― |
| Fludarabine, Azacitidine, Cytarabine, Decitabine, Venetoclax, Etoposide, Idarubicin, Mitoxantrone, Dfp-10917, Cladribine | Phase III | Leukemia, Myeloid, Acute | Recruiting | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Apr 11, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Delta-Fly Pharma, Inc. (JP:4598) have in its pipeline
Delta-Fly Pharma, Inc. JP:4598 is currently developing the following drugs: Venetoclax, Dfp-10917, Dfp-14927, Fludarabine, Azacitidine, Cytarabine, Decitabine, Venetoclax, Etoposide, Idarubicin, Mitoxantrone, Dfp-10917, Cladribine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.